| Literature DB >> 32587678 |
Sunil Shrestha1, Krisha Danekhu2, Bhuvan Kc3, Subish Palaian4, Mohamed Izham Mohamed Ibrahim5.
Abstract
BACKGROUND: Bibliometric analyses have been used previously to study the measures of quality and impact of research performed in several health-related areas such as adverse drug reactions (ADRs) and pharmacovigilance (PV), etc. This method can assess the research performance of publications quantitatively and statistically. There is no evidence of bibilometric studies analyzing ADRs and PV from Nepal. Therefore, the present study aimed to assess scientific output on ADRs and PV-related research activities in Nepal using a bibliometric analysis of publications from 2004 January to December 2018, that is, 15 years.Entities:
Keywords: Nepal; adverse drug reactions; bibliometry; drug safety; pharmacovigilance
Year: 2020 PMID: 32587678 PMCID: PMC7294481 DOI: 10.1177/2042098620922480
Source DB: PubMed Journal: Ther Adv Drug Saf ISSN: 2042-0986
MeSH keywords (for search in electronic databases both in English).
| • Adverse Drug reaction |
Figure 1.Flowchart of the operational framework of a bibliometric study.
Figure 2.Annual number of ADR and PV publications in Nepal.
ADR, adverse drug reaction; PV, pharmacovigilance.
Average number of authors per article.
| Average number of authors | Frequency ( | Percent (%) |
|---|---|---|
| 1 | 3 | 2.4 |
| 2 | 20 | 16.1 |
| 3 | 28 | 22.6 |
| 4 | 24 | 19.4 |
| 5 | 24 | 19.4 |
| 6 | 15 | 12.1 |
| 7 | 7 | 5.6 |
| 8 | 2 | 1.6 |
| 10 | 1 | 0.8 |
| Total | 124 | 100.0 |
List of journals with IF and ISSN.
| Sample number | Name of journal | Frequency | Percent | Journal impact factor/SJR 2017 | ISSN | H-index |
|---|---|---|---|---|---|---|
| 1 |
| 1 | 0.8 | NA | NA | NA |
| 2 |
| 1 | 0.8 | 0.62/Q1 | 00029459, 15536467 | 49 |
| 3 |
| 1 | 0.8 | 1.1/Q1 | 15426270, 10600280 | 100 |
| 4 |
| 1 | 0.8 | 0.1/Q4 | 2045080X | 1 |
| 5 |
| 1 | 0.8 | 0.62/Q2 | 22338276, 22338268 | 3 |
| 6 |
| 1 | 0.8 | NA | 2467-9100, 2091-0576 | NA |
| 7 |
| 5 | 4.0 | 0.32/Q2 | 18361935 | 16 |
| 8 |
| 1 | 0.8 | 0.78/Q2 | 20506511 | 19 |
| 9 |
| 1 | 0.8 | 0.69/Q2 | 17560500 | 52 |
| 10 |
| 2 | 1.6 | 0.97/Q2 | 11791438 | 18 |
| 11 |
| 1 | 0.8 | 0.33/Q3 | 10872108 | 35 |
| 12 |
| 1 | 0.8 | NA | NA | NA |
| 13 |
| 1 | 0.8 | 1.45/Q1 | 1145916 | 112 |
| 14 |
| 2 | 1.6 | NA | 1994-7208 | NA |
| 15 |
| 1 | 0.8 | 0.37/Q3 | 09751564, 02537176 | 13 |
| 16 |
| 1 | 0.8 | 0.41/Q3 | 19983751, 02537613 | 49 |
| 17 |
| 1 | 0.8 | NA | 2279-0780 | NA |
| 18 |
| 1 | 0.8 | NA | 2249-9571 | NA |
| 19 |
| 1 | 0.8 | NA | 2581-4303 | NA |
| 20 |
| 2 | 1.6 | NA | 2476-2431 | NA |
| 21 |
| 1 | 0.8 | NA | 2249-1848 | NA |
| 22 |
| 2 | 1.6 | 0.32/Q3 | 9246479 | 19 |
| 23 |
| 2 | 1.6 | NA | 2616-0323, 2616-0390 | NA |
| 24 |
| 3 | 2.4 | NA | 2091-2412, 2091-2889 | NA |
| 25 |
| 7 | 5.6 | 0.35/Q3 | 0973709X | 22 |
| 26 |
| 3 | 2.4 | NA | 2091-065, 2091-0673 | NA |
| 27 |
| 2 | 1.6 | NA | 2070-4240 | NA |
| 28 |
| 7 | 5.6 | NA | 0259-0972 | NA |
| 29 |
| 1 | 0.8 | NA | 2091-1785, 2091-1793 | NA |
| 30 |
| 1 | 0.8 | NA | 2542-2618, 2392-4632 | NA |
| 31 |
| 1 | 0.8 | 0.15/Q4 | 19996217 | 8 |
| 32 |
| 1 | 0.8 | 0.11/Q4 | 19907974, 19907982 | 6 |
| 33 |
| 1 | 0.8 | NA | 0253-8261 | NA |
| 34 |
| 1 | 0.8 | NA | 2863, 2565-4845 | NA |
| 35 |
| 1 | 0.8 | 0.59/Q2 | 1477092X, 10781552 | 26 |
| 36 |
| 6 | 4.8 | 0.18/Q3 | 15609014 | 10 |
| 37 |
| 1 | 0.8 | 0.41/Q3 | 8971900 | 21 |
| 38 |
| 2 | 1.6 | 0.16/Q3 | 1445937X | 19 |
| 39 |
| 2 | 1.6 | NA | 2091-2862, 2350-8949 | NA |
| 40 |
| 2 | 1.6 | NA | 2362-1281, 2467-9119 | NA |
| 41 |
| 2 | 1.6 | 0.13/Q4 | 282715 | 15 |
| 42 |
| 1 | 0.8 | 0.28/Q3 | 309982 | 35 |
| 43 |
| 1 | 0.8 | NA | 1816-8752 | NA |
| 44 |
| 10 | 8.1 | 0.17/Q3 | 18122078, 18122027 | 20 |
| 45 |
| 1 | 0.8 | NA | 2091-0185, 2091-0193 | NA |
| 46 |
| 5 | 4.0 | NA | 2091-0231, 2091-167X | NA |
| 47 |
| 2 | 1.6 | NA | 2091-0800 | NA |
| 48 |
| 1 | 0.8 | NA | 1813-1948, 1813-1956 | NA |
| 49 |
| 2 | 1.6 | NA | 1999-9623, 1999-8546 | NA |
| 50 |
| 2 | 1.6 | NA | 2091-2978, 2382-5464 | NA |
| 51 |
| 3 | 2.4 | 0.36/Q2 | 1011601X | 33 |
| 52 |
| 4 | 3.2 | 0.16/Q4 | 18278620 | 20 |
| 53 |
| 3 | 2.4 | 0.45/Q2 | 1885642X, 18863655 | 17 |
| 54 |
| 1 | 0.8 | 0.9/Q1 | 15517411 | 33 |
| 55 |
| 2 | 1.6 | NA | 1818-9741, 2091-0959 | NA |
| 56 |
| 1 | 0.8 | 0.69/Q1 | 13190164 | 30 |
| 57 |
| 1 | 0.8 | NA | NA | NA |
| 58 |
| 1 | 0.8 | 0.32/Q3 | 9246479 | 19 |
| 59 |
| 2 | 1.6 | NA | 1531-2976 | NA |
| 60 |
| 1 | 0.8 | 0 | 1583526X, 15835251 | 4 |
| 61 |
| 1 | 0.8 | 0.33/Q3 | 494755 | 30 |
| 62 |
| 2 | 1.6 | 1.78/Q1 | 15244733, 10983015 | 82 |
| Total | 124 | 100.0 |
NA, not available; –, not given.
IF, impact factor; ISSN, international standard serial number; SJR, scientific journal ranking.
Type of publications recorded.
| Type of publication | Frequency | Percent |
|---|---|---|
| Original research article | 52 | 41.9 |
| Case report | 39 | 31.2 |
| Review article | 12 | 9.7 |
| Short communication | 10 | 8.1 |
| Letter to editor | 7 | 5.6 |
| Brief report | 2 | 1.6 |
| Case series | 1 | 0.8 |
| Education forum | 1 | 0.8 |
| Total | 124 | 100 |
Research categories and research domains.
| Sample number | Category | Research domains |
| % |
|---|---|---|---|---|
| 1. | ADRs (incidence, types of therapeutic categories, prevention and management) | 88 | 74.1 | |
| Cutaneous adverse drug reactions | 33 | 37.5 | ||
| ADRs due to generally prescribed drugs | 12 | 13.63 | ||
| ADRs related to antitubercular medicines | 11 | 12.5 | ||
| ADRs related to chemotherapy drugs | 5 | 5.7 | ||
| ADRs due to antihypertensive medicines | 5 | 5.7 | ||
| ADRs related neuropsychiatric manifestations | 3 | 3.4 | ||
| ADRs due to antileprotic medicines | 2 | 2.2 | ||
| ADRs related to oral hypoglycemic agents | 1 | 1.1 | ||
| ADRs due to anti filarial medicines | 1 | 1.1 | ||
| Others therapeutic categories | 15 | 17.0 | ||
| 2. | Policy and suggestions for strengthening national and regional pharmacovigilance centers of Nepal | 18 | 14.5 | |
| 3. | Knowledge, attitude and practice of pharmacovigilance and ADR among healthcare professionals and consumers | 6 | 4.8 | |
| 4. | Educational intervention health care professionals and consumers pharmacovigilance and ADR among | 7 | 5.6 | |
| 5. | Drug withdrawal due to ADRs | 1 | 0.8 | |
ADRs, adverse drug reactions.
Figure 3.Word cloud generator of PV and ADR keywords.
ADR, adverse drug reaction; PV, pharmacovigilance.